TrovaGene, Inc. (TROV) EPS Estimated At $-0.08; Zweig-Dimenna Associates Has Lifted Lam Research (LRCX) Holding

April 8, 2018 - By Hazel Jackson

Lam Research Corporation (NASDAQ:LRCX) Logo

Zweig-Dimenna Associates Llc increased Lam Research Corp (LRCX) stake by 1156.79% reported in 2017Q4 SEC filing. Zweig-Dimenna Associates Llc acquired 32,390 shares as Lam Research Corp (LRCX)’s stock rose 8.53%. The Zweig-Dimenna Associates Llc holds 35,190 shares with $6.48M value, up from 2,800 last quarter. Lam Research Corp now has $31.07B valuation. The stock decreased 2.24% or $4.37 during the last trading session, reaching $190.65. About 3.12M shares traded. Lam Research Corporation (NASDAQ:LRCX) has risen 58.54% since April 8, 2017 and is uptrending. It has outperformed by 46.99% the S&P500.

Analysts expect TrovaGene, Inc. (NASDAQ:TROV) to report $-0.08 EPS on May, 9.They anticipate $0.18 EPS change or 69.23% from last quarter’s $-0.26 EPS. After having $-0.06 EPS previously, TrovaGene, Inc.’s analysts see 33.33% EPS growth. The stock decreased 3.13% or $0.011 during the last trading session, reaching $0.337. About 572,923 shares traded. TrovaGene, Inc. (NASDAQ:TROV) has declined 66.35% since April 8, 2017 and is downtrending. It has underperformed by 77.90% the S&P500.

Investors sentiment decreased to 0.53 in 2017 Q4. Its down 0.32, from 0.85 in 2017Q3. It dropped, as 7 investors sold TrovaGene, Inc. shares while 10 reduced holdings. 3 funds opened positions while 6 raised stakes. 2.44 million shares or 51.68% less from 5.05 million shares in 2017Q3 were reported. Goldman Sachs Group Incorporated reported 15,358 shares stake. Tci Wealth has 300 shares for 0% of their portfolio. State Street accumulated 13,300 shares or 0% of the stock. Captrust Fincl accumulated 62,500 shares or 0% of the stock. Raymond James Associates invested in 23,000 shares or 0% of the stock. Two Sigma Secs Limited Liability Company accumulated 81,627 shares. Moreover, Jpmorgan Chase & has 0% invested in TrovaGene, Inc. (NASDAQ:TROV) for 811 shares. Meeder Asset Inc holds 5,433 shares. California Public Employees Retirement Systems owns 77,200 shares. Deutsche Fincl Bank Ag invested 0% of its portfolio in TrovaGene, Inc. (NASDAQ:TROV). Geode Cap Ltd Liability holds 0% or 139,330 shares in its portfolio. Moreover, Fincl Bank Of New York Mellon has 0% invested in TrovaGene, Inc. (NASDAQ:TROV) for 56,488 shares. Barclays Pcl invested in 0% or 25,000 shares. Messner Smith Theme Value Inv Management Ca accumulated 23,850 shares or 0.01% of the stock. Virtu Fin Lc has 0% invested in TrovaGene, Inc. (NASDAQ:TROV).

Among 8 analysts covering TrovaGene (NASDAQ:TROV), 1 have Buy rating, 1 Sell and 6 Hold. Therefore 13% are positive. TrovaGene had 19 analyst reports since August 14, 2015 according to SRatingsIntel. The firm earned “Buy” rating on Monday, June 12 by Maxim Group. The rating was initiated by H.C. Wainwright with “Buy” on Thursday, December 21. Maxim Group maintained the stock with “Buy” rating in Wednesday, August 16 report. On Friday, March 11 the stock rating was downgraded by Janney Capital to “Neutral”. The firm earned “Sector Perform” rating on Tuesday, April 26 by Leerink Swann. As per Friday, August 14, the company rating was initiated by Leerink Swann. The company was downgraded on Thursday, March 16 by PiperJaffray. H.C. Wainwright maintained the shares of TROV in report on Tuesday, March 6 with “Buy” rating. The company was downgraded on Monday, April 25 by Piper Jaffray. Maxim Group downgraded the stock to “Hold” rating in Friday, November 10 report.

Trovagene, Inc., a clinical-stage, precision medicine oncology therapeutics company, develops oncology therapeutics for cancer care by leveraging its proprietary Precision Cancer Monitoring technology in tumor genomics. The company has market cap of $18.63 million. The Company’s lead drug candidate, PCM-075, is a Polo-like Kinase 1 selective adenosine triphosphate competitive inhibitor. It currently has negative earnings. The PCM-075 is an orally bioavailable, which has explored in preclinical antitumor activity as a single agent and in synergy combinations with approximately 10 different chemotherapeutics and targeted therapies, such as Zytiga (abiraterone acetate), Beleodaq (belinostat), Quizartinib, a development stage FLT3 inhibitor, and Velcade (bortezomib) in acute myeloid leukemia (AML), metastatic castration-resistant prostate cancer, and other liquid and solid tumor cancers.

Since October 13, 2017, it had 0 insider buys, and 11 sales for $20.63 million activity. O’Dowd Sarah A sold $390,194 worth of Lam Research Corporation (NASDAQ:LRCX) on Thursday, March 8. 4,656 Lam Research Corporation (NASDAQ:LRCX) shares with value of $987,770 were sold by LORD PATRICK J. $146,318 worth of Lam Research Corporation (NASDAQ:LRCX) shares were sold by NEWBERRY STEPHEN G. $3.67 million worth of Lam Research Corporation (NASDAQ:LRCX) was sold by ARCHER TIMOTHY. Another trade for 11,200 shares valued at $2.52 million was made by Anstice Martin B on Wednesday, March 21. $5.47 million worth of Lam Research Corporation (NASDAQ:LRCX) shares were sold by Varadarajan Seshasayee. Gottscho Richard A also sold $3.54M worth of Lam Research Corporation (NASDAQ:LRCX) shares.

Investors sentiment increased to 1.08 in 2017 Q4. Its up 0.06, from 1.02 in 2017Q3. It is positive, as 40 investors sold LRCX shares while 262 reduced holdings. 112 funds opened positions while 215 raised stakes. 140.89 million shares or 3.74% less from 146.35 million shares in 2017Q3 were reported. Spark Invest Ltd Liability Co accumulated 12,100 shares. Kbc Group Inc Nv accumulated 316,776 shares. Columbus Circle Invsts has invested 1.02% of its portfolio in Lam Research Corporation (NASDAQ:LRCX). Delphi Management Inc Ma invested in 13,987 shares or 1.47% of the stock. Voya Inv stated it has 0.55% in Lam Research Corporation (NASDAQ:LRCX). Arvest Bancorp Trust Division accumulated 61,420 shares or 0.79% of the stock. Meiji Yasuda Life Insurance reported 9,945 shares. Livforsakringsbolaget Skandia Omsesidigt owns 7,654 shares. Moreover, Wells Fargo & Mn has 0.05% invested in Lam Research Corporation (NASDAQ:LRCX). Dana Advsrs Incorporated reported 229,811 shares. Jennison Assoc Ltd Com reported 0.05% in Lam Research Corporation (NASDAQ:LRCX). Morgan Stanley holds 0.04% in Lam Research Corporation (NASDAQ:LRCX) or 787,748 shares. Salem Counselors Incorporated reported 77 shares stake. Highland Mgmt Limited owns 3,737 shares. Murphy Management accumulated 6,500 shares.

Zweig-Dimenna Associates Llc decreased Mastercard Incorporated (Call) (NYSE:MA) stake by 243,640 shares to 56,300 valued at $8.52 million in 2017Q4. It also reduced Bank Of Nt Butterfield&Son L stake by 103,783 shares and now owns 200,495 shares. Facebook Inc (NASDAQ:FB) was reduced too.

Among 27 analysts covering Lam Research Corporation (NASDAQ:LRCX), 26 have Buy rating, 0 Sell and 1 Hold. Therefore 96% are positive. Lam Research Corporation had 84 analyst reports since September 17, 2015 according to SRatingsIntel. KeyBanc Capital Markets maintained the shares of LRCX in report on Sunday, November 19 with “Buy” rating. The stock of Lam Research Corporation (NASDAQ:LRCX) earned “Overweight” rating by Morgan Stanley on Thursday, January 25. The rating was maintained by Cowen & Co with “Outperform” on Thursday, December 10. As per Thursday, August 3, the company rating was downgraded by Citigroup. The firm has “Outperform” rating by RBC Capital Markets given on Friday, January 13. The firm has “Buy” rating by Susquehanna given on Tuesday, March 6. Goldman Sachs upgraded the shares of LRCX in report on Monday, December 19 to “Buy” rating. RBC Capital Markets maintained the shares of LRCX in report on Thursday, October 22 with “Underperform” rating. Credit Agricole upgraded Lam Research Corporation (NASDAQ:LRCX) on Friday, September 25 to “Buy” rating. The rating was upgraded by CLSA on Friday, September 25 to “Buy”.

Lam Research Corporation (NASDAQ:LRCX) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: